A Single Ascending Dose of HRS-2162 in Healthy Subjects
NCT07195604 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64
Last updated 2025-11-17
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-2162 injection in a single dose in healthy subjects, as well as the characteristics of PK/PD
Conditions
- Reversal of Neuromuscular Blockade
Interventions
- DRUG
-
HRS-2162
HRS-2162
- DRUG
-
Placebo
Sponsors & Collaborators
-
Fujian Shengdi Pharmaceutical Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-09-25
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of Nitrazine in the Treatment of ALS
NCT04950647 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis
NCT02542787 ·Status: COMPLETED ·Phase: PHASE2
-
FHND1002 for ALS Treatment: Phase 2
NCT07138014 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study Exploring the PK/PD Relationship of QRL-101 in Adults With ALS
NCT06714396 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT01281631 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity
NCT05311215 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of CVN424 in Healthy Subjects
NCT03657030 ·Status: COMPLETED ·Phase: PHASE1
-
XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.
NCT00298623 ·Status: COMPLETED ·Phase: PHASE3
-
ALS Phase II Study of NX210c
NCT06365216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Long-term Extension Study of TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis(ALS)
NCT00230074 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
NCT04165486 ·Status: RECRUITING ·Phase: PHASE1
-
Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors
NCT05234762 ·Status: UNKNOWN ·Phase: PHASE2
-
HEALEY ALS Platform Trial - Regimen D Pridopidine
NCT04615923 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy Confirmation Study of NPC-09
NCT04671472 ·Status: COMPLETED ·Phase: PHASE3
-
Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex
NCT02401841 ·Status: UNKNOWN
-
Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00072709 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
NCT04990219 ·Status: TERMINATED ·Phase: PHASE1
-
First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers
NCT05642546 ·Status: COMPLETED ·Phase: PHASE1
-
Sugammadex and Neostigmine at Shallow Neuromuscular Blockade
NCT00895609 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
NCT04176224 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05039099 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 ALKS 1140 in Healthy Adults
NCT05019105 ·Status: TERMINATED ·Phase: PHASE1
-
Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS
NCT05214963 ·Status: COMPLETED ·Phase: NA
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2